Coal Tar

Summary

Coal Tar (CHEMBL2108232) is a phase-3 clinical-stage unknown; indicated across 3 conditions including psoriasis and seborrheic dermatitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108232
Name	Coal Tar
Type	Unknown
Max phase	3

Also known as: Alphosyl, Capasal, Clinitar, Coal tar, Coal tar (in shampoo), Coal tar (non shampoo), Coal tar solution, prepared, colloidal, crude, refined, Cocois co

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
seborrheic dermatitis	4	MONDO:0006608	EFO:1000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03461302	PHASE4	UNKNOWN	Efficacy of Topical Coal Tar in Children With Atopic Dermatitis
NCT02644954	PHASE3	UNKNOWN	Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis
NCT05105139	Not specified	COMPLETED	Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).